Yupelri

Active Ingredient(s): Revefenacin
FDA Approved: * November 9, 2018
Pharm Company: * THERAVANCE BIOPHARMA
Category: Lungs (Pulmonary)

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that makes it progressively harder to breathe. It occurs when the airways and lung tissue become damaged, leading to reduced airflow and less efficient oxygen exchange in the lungs. COPD develops gradually over time, and while it cannot currently be cured, treatments and lifestyle changes can help control symptoms and slow disease progression. Early diagnosis and treatment are recommended. The condition includes two r... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Yupelri 175 ug/3ml Respiratory (Inhalation) Solution
NDC: 49502-806
Labeler:
Mylan Specialty L.p.